Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

National Health Research Policy The establishment of a Department of Health Research (DHR) in the Ministry of Health is recognition by the GOI of the key role that health research should play in the nation.

Annual report of the Executive Director to the Discharge on measures taken in the light of the Discharge s recommendations of 2012 in respect of the implementation of the budget of 2010 (Article 131(2)

IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?) WHAT An EU project (FP7) financed by the

Directive 2011/24/EU on the application of patients rights in cross-border healthcare EPF for a patient-centred implementation Introduction These recommendations have been developed by the European Patients

CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

SPEECH FOR THE PANEL ON BUSINESS CLIMATE AND INVESTMENT OPPORTUNITIES, Support for Ukraine Conference, 28 April 2015 Ministers, friends, ladies and gentlemen, Ukraine has extraordinary potential. We all

Presentation by Mr Richard Bruton, Minister of Jobs, Enterprise and Innovation to the Industry Research and Energy Committee of the European Parliament, Brussels Wednesday 23/1/2013 Check against Delivery

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed

FRAMEWORK FOR ADVANCING TRANSATLANTIC ECONOMIC INTEGRATION BETWEEN THE EUROPEAN UNION AND THE UNITED STATES OF AMERICA We, leaders of the European Union and the United States of America: Believing that

List of Guiding Principles Promoting Good Governance in the Pharmaceutical Sector 1 1. Good governance in the pharmaceutical sector 1.1 The List of Guiding Principles is based on recognition by all participants

EUROPEAN COMMISSION Brussels, 2.7.2014 SWD(2014) 214 final COMMISSION STAFF WORKING DOCUMENT Report on the Implementation of the Communication 'Unleashing the Potential of Cloud Computing in Europe' Accompanying

Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended

FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

Achievements and challenges of the single market S&D responses to citizens top 10 concerns The European economic model must be based on three principles: competition which stimulates, co-operation which

PhaRma FIGURES 2015 The pharmaceutical sector in Belgium : A cornerstone of the Belgian economy, a laboratory of hope for patients The core figures of 2015 confirm the strength of the pharmaceutical sector

EUROPEAN COMMISSION Brussels, 13.5.2015 COM(2015) 271 final Recommendation for a COUNCIL RECOMMENDATION on the 2015 National Reform Programme of Portugal and delivering a Council opinion on the 2015 Stability

PRESS RELEASE Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform Pivot Park Screening Centre in Oss will play an important role in a new pan-european drug

STRATEGIC PLAN 2013/2014 TO 2015/2016 1. WCO Strategic Plan Introduction 1. The purpose of this document is to present the WCO Strategic Plan that was approved by the Council in June 2013 for the years

Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While

Healthcare Coalition on Data Protection Recommendations and joint statement supporting citizens interests in the benefits of data driven healthcare in a secure environment Representing leading actors in

ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL

LC Paper No. CB(2)441/15-16(01) 15 December 2015 For information Legislative Council Panel on Health Services Subcommittee on Issues Relating to the Development of Chinese Medicine Policy and direction

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

Novartis Investigator Initiated Trials (IITs) Guidelines Introduction and background As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to

ViiV Healthcare s Universal Health Coverage for People Living with HIV (PLHIV), Policy The Issue Universal Health Coverage (UHC) means that all people receive the quality health services they need without

exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

Secretariat AIM ASSOCIATION INTERNATIONALE DE LA MUTUALITE ABOUT AIM AIM CONTRIBUTION TO THE COMMISSION S GREEN PAPER ON THE EUROPEAN WORKFORCE FOR HEALTH BRUSSELS, 2 APRIL 2009 The Association Internationale

& Patient Organisations in Ireland in 214 Chugai Pharma UK LTD believes it is important to be transparent regarding interactions with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and

COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 12.5.2009 C(2009) 3200 final COMMISSION RECOMMENDATION of 12.5.2009 on the implementation of privacy and data protection principles in applications supported

The digital economy at the heart of the economic and social transition of EU Regions Digital Entrepreneurship: The EU vision, strategy and actions EITO Task Force Meeting, 14th November 2014 Michael Berz

Spanish non paper Public Private Partnership as Industrial Research and Innovation Instruments The way forward The purpose of this document is to capture the view of the Spanish Presidency of the European

www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Consolidation in the generics sector Integrating business development Cross-cultural negotiations Self-reporting

CALL FOR PROPOSALS 2015 CANADA/GERMANY JOINT PROGRAM DEADLINE: JANUARY 15 TH, 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

A European Roadmap for Businesses Towards a Sustainable and Competitive Enterprise A EUROPEAN ROADMAP FOR BUSINESSES Towards a Sustainable and Competitive Enterprise AN OPEN INITIATIVE FOR ALL ENTERPRISES

The inclusion of cross-cutting issues in the EU policy: Gender topics, regional development and innovation Liliana Rodrigues Member of European Parliament Committee on Regional Development Committee on

On RFID The Next Step to THE INTERNET OF THINGS Information of the Presidency 2832nd Council meeting, Competitiveness (Internal Market, Industry and Research), Brussels, 22-23 November 2007 A. Background